Number of patients with potentially contraindicated drug-drug interactions Number of patients with a potential drug interaction (per 10000 person years).

<p>Number of patients with potentially contraindicated drug-drug interactions Number of patients with a potential drug interaction (per 10000 person years).</p

Number of patients with contraindicated drug-drug interactions Number of patients with a potential drug interaction (per 10000 person years).

<p>Number of patients with contraindicated drug-drug interactions Number of patients with a potential drug interaction (per 10000 person years).</p

Percentage of general practitioners and specialists with at least one potential drug-drug interaction (DDI) % physicians with at least 1 potential DDI.

<p>Percentage of general practitioners and specialists with at least one potential drug-drug interaction (DDI) % physicians with at least 1 potential DDI.</p

Characteristics of glioma cases and controls.

<p>Characteristics of glioma cases and controls.</p

Risk of glioma in patients using etodoloac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib, lumiracoxib or diclofenac.

<p>Risk of glioma in patients using etodoloac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib, lumiracoxib or diclofenac.</p

Risk of meningioma in relation to number of prescriptions for anti-diabetic drugs.

<p>Risk of meningioma in relation to number of prescriptions for anti-diabetic drugs.</p

Characteristics of meningioma cases and controls.

<p>Characteristics of meningioma cases and controls.</p